Rimini Street (NASDAQ:RMNI) reported quarterly sales of $101.20 million which beat the analyst consensus estimate of $99.22 million by 2.00 percent. This is a 10.46 percent increase over sales of $91.61 million the same period last year.
Nabriva Therapeutics Announces Topline Results From Phase 1 Trial Of XENLETA In Adult Patients With Cystic Fibrosis
Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced positive topline results